Search
4D Molecular Therapeutics Inc
FDMTAdd to Watchlist
10.180USD
+0.110+1.09%
Close 07-31 16:00（ET）Quotes delayed by 15 min
532.17MMarket Cap
LossP/E TTM
More Details of 4D Molecular Therapeutics Inc Company
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.
4D Molecular Therapeutics Inc Info
Ticker SymbolFDMT
Company name4D Molecular Therapeutics Inc
IPO dateDec 11, 2020
CEOKirn (David)
Number of employees227
Security typeOrdinary Share
Fiscal year-endDec 11
Address5858 Horton Street #455
CityEMERYVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94608
Phone15105052680
Websitehttps://4dmoleculartherapeutics.com/
Ticker SymbolFDMT
IPO dateDec 11, 2020
CEOKirn (David)
Company Executives of 4D Molecular Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. David Kirn, M.D.
Dr. David Kirn, M.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.48M
-3.93%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
100.00K
--
Dr. Fariborz (Fred) Kamal, Ph.D.
Dr. Fariborz (Fred) Kamal, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
5.94K
--
Dr. Jacob M. Chacko, M.D.
Dr. Jacob M. Chacko, M.D.
Independent Director
Independent Director
--
--
Ms. Susannah Gray
Ms. Susannah Gray
Independent Director
Independent Director
--
--
Dr. Charles P. Theuer, M.D., Ph.D.
Dr. Charles P. Theuer, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Nancy Miller-Rich
Ms. Nancy Miller-Rich
Independent Director
Independent Director
--
--
Ms. Shawn Cline Tomasello
Ms. Shawn Cline Tomasello
Independent Director
Independent Director
--
--
Dr. Scott Bizily, J.D., Ph.D.
Dr. Scott Bizily, J.D., Ph.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Robert (Bob) Kim, M.D.
Dr. Robert (Bob) Kim, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. David Kirn, M.D.
Dr. David Kirn, M.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.48M
-3.93%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
100.00K
--
Dr. Fariborz (Fred) Kamal, Ph.D.
Dr. Fariborz (Fred) Kamal, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
5.94K
--
Dr. Jacob M. Chacko, M.D.
Dr. Jacob M. Chacko, M.D.
Independent Director
Independent Director
--
--
Ms. Susannah Gray
Ms. Susannah Gray
Independent Director
Independent Director
--
--
Dr. Charles P. Theuer, M.D., Ph.D.
Dr. Charles P. Theuer, M.D., Ph.D.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of 4D Molecular Therapeutics Inc?
The top five shareholders of 4D Molecular Therapeutics Inc are: Dr. David Kirn, M.D.
How many institutions hold shares of 4D Molecular Therapeutics Inc (FDMT)?
As of 2026Q1, 363 institutions hold shares of 4D Molecular Therapeutics Inc, with a combined market value of approximately 54.90M, accounting for 105.02% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -3486537.00.